Aesica, a global contract manufacturing organisation (CMO), has announced a partnership with the UK’s University of Nottingham to explore the development of alternative methods in amide bond synthesis.

Amide bond formation is fundamental part of pharmaceutical manufacturing, and is utilised in 84% of a set of drug candidates.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The partnership’s aim is to revolutionise traditional amide formation techniques by generating alternative, eco-friendly and chemically versatile methods for amide bond formation.

According to the company, the approach will be commercially available in the next two to three months and the company is already actively seeking commercial opportunities to work with potential compounds that could benefit from this novel technology.

"The partnership’s aim is to revolutionise traditional amide formation techniques by generating alternative, eco-friendly and chemically versatile methods for amide bond formation."

Aesica envisages this new development will lower production costs whilst offering the potential of higher chemical yields.

See Also:

University of Nottingham Synthetic Organic Chemistry professor Simon Woodward said that one of the departments goals has been to see this novel technology used in larger scale industrial environments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We look forward to collaborating with Aesica and seeing the full commercial potential of this novel technology in API manufacture," said Woodward.

Aesica Pharmaceuticals Technology Development director Barrie Rhodes said that the new amide production technology will enable cheaper and simpler routes to market for many compounds.

"Professor Woodward’s ability to carry out high calibre research coupled with our desire to bring new economically important and innovative technologies to the market is the basis for a truly collaborative partnership," Rhodes said.